Search Results for ""drugs for""
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for "drugs for". Results 1891 to 1900 of 2581 total matches.

In Brief: Airborne

   
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005  (Issue 1199)
The Medical Letter ® On Drugs and Therapeutics 1 FORWARDING OR COPYING IS A VIOLATION OF U.S ...
Patients may be asking about Airborne, a dietary supplement that is being heavily promoted for prevention and treatment of colds. It contains 7 herbal extracts, 3 vitamins, 2 amino acids, selenium, zinc and many other ingredients. Airborne Jr is available for children. There are some concerns. First, there is no conclusive evidence that this product or any of its ingredients prevents colds or shortens their duration. Second, the adult tablet contains 1 g of vitamin C, and the directions for use advise taking 1 tablet at the first sign of a cold and repeating the dose every 3 hours as...
Med Lett Drugs Ther. 2005 Jan 3;47(1199):4 |  Show IntroductionHide Introduction

Clarification: Half-Life of Heroin

   
The Medical Letter on Drugs and Therapeutics • Feb 29, 2016  (Issue 1489)
The Medical Letter® on Drugs and Therapeutics Volume 58 (Issue 1489) February 29, 2016 Published ...
A reader expressed concern that a statement in our article Naloxone (Narcan) Nasal Spray for Opioid Overdose (Med Lett Drugs Ther 2016; 58:1) might be misleading. We stated that heroin has a half-life of 2-6 minutes, which is correct, but heroin is a prodrug that is rapidly metabolized to 6-acetylmorphine and morphine. The risk of respiratory depression is related to those active metabolites, and it may persist well beyond the clearance of heroin from the blood.
Med Lett Drugs Ther. 2016 Feb 29;58(1489):32 |  Show IntroductionHide Introduction

In Brief: Tafamidis (Vyndaqel; Vyndamax) for Transthyretin Amyloid Cardiomyopathy

   
The Medical Letter on Drugs and Therapeutics • Jan 27, 2020  (Issue 1590)
-mediated amyloid cardiomyopathy (ATTR-CM). Tafamidis is the first drug to be approved ...
The FDA has approved tafamidis, an oral transthyretin stabilizer, in 2 different formulations (see Table 1) for treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Tafamidis is the first drug to be approved in the US for this indication. Patisiran (Onpattro), a transthyretin-directed small interfering RNA, and inotersen (Tegsedi), a transthyretin-directed antisense oligonucleotide, were both recently approved for hereditary transthyretin amyloid polyneuropathy.THE DISEASE — ATTR-CM is a progressive life-threatening disease caused by destabilization of the...
Med Lett Drugs Ther. 2020 Jan 27;62(1590):16 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022  (Issue 1642)
on vaccines and drugs for COVID-19 can be found in the COVID-19 Resources section of our website ...
On January 3, the FDA amended its Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) to incorporate the following changes. The anti-SARS-CoV-2 antibody combinations casirivimab plus imdevimab (REGEN-COV) and bamlanivimab plus etesevimab are not active against the Omicron variant of SARS-CoV-2.
Med Lett Drugs Ther. 2022 Jan 24;64(1642):16 |  Show IntroductionHide Introduction

Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
, and hepatotoxity are common with use of the drug. PREGNANCY AND LACTATION — In animal studies, administration ...
The alkylating agent lurbinectedin (Zepzelca – Jazz) has received accelerated approval from the FDA for treatment of metastatic small-cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. Accelerated approval was based on the overall response rate and duration of response. About 13-15% of lung cancers are small-cell cancers. Most SCLCs occur in patients who are current or former smokers.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e198-9 |  Show IntroductionHide Introduction

Sinemet CR For Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991  (Issue 854)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Controlled-release carbidopa/levodopa (Sinemet CR - Dupont Pharma) was recently approved by the US Food and Drug Administration for treatment of Parkinson's disease. The new formulation of this old combination (Sinemet) has the drugs suspended in a polymeric matrix that erodes slowly in the gastrointestinal tract.
Med Lett Drugs Ther. 1991 Oct 4;33(854):92-3 |  Show IntroductionHide Introduction

Fluoxetine Sarafem For Premenstrual Dysphoric Disorder

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001  (Issue 1096)
The Medical Letter  On Drugs and Therapeutics Published by The Medical Letter, Inc. • 1000 Main ...
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) previously sold only as Prozac, is now also marketed as Sarafem for treatment of premenstrual dysphoric disorder (PMDD). Generic fluoxetine is expected to be available sometime this year.
Med Lett Drugs Ther. 2001 Jan 22;43(1096):5-6 |  Show IntroductionHide Introduction

Dexmethylphenidate (Focalin) For ADHD

   
The Medical Letter on Drugs and Therapeutics • May 13, 2002  (Issue 1130)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Dexmethylphenidate (Focalin - Novartis), a new formulation of methylphenidate (Ritalin, and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is the d-threo-enantiomer of racemic methylphenidate. "Now the right half may be all your patients need," said a recent ad. Focalin is the third new methylphenidate formulation marketed in the last two years.
Med Lett Drugs Ther. 2002 May 13;44(1130):45-6 |  Show IntroductionHide Introduction

Rasburicase (Elitek) for Hyperuricemia

   
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002  (Issue 1143)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Med Lett Drugs Ther. 2002 Nov 11;44(1143):96-7 |  Show IntroductionHide Introduction

Parcopa: A Rapidly Dissolving Formulation of Carbidopa/Levodopa

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 2005  (Issue 1201)
Letter ® On Drugs and Therapeutics IN THIS ISSUE Volume 47 (Issue 1201) January 31, 2005 ...
An orally dissolving, immediate-release tablet formulation of carbidopa/levodopa (Parcopa - Schwarz) that can be taken without water is now available for treatment of Parkinson's disease.
Med Lett Drugs Ther. 2005 Jan 31;47(1201):12 |  Show IntroductionHide Introduction